Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-37 T cells in CD37+ hematologic malignancies
NCT04136275Phase 1Completed
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-37 T cells in hematologic malignancy, leukemia, lymphoma and 3 more. Started Jun 2020; status: completed.
02
Drugs
CAR-37 T cells
03
Conditions
hematologic malignancyleukemialymphomaB cell lymphomaT-cell lymphoma
Beyond the preview
Go deeper on NCT04136275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136275.